Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.
about
Checkpoint Inhibitors and Their Application in Breast CancerTargeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.Elevated T cell activation score is associated with improved survival of breast cancer.CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.High CTLA-4 expression correlates with poor prognosis in thymoma patients.Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients.Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer.Mechanisms of immune evasion in breast cancer.Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cellsDiagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients
P2860
Q26745442-537982E4-32E4-47D8-BDD5-3FBB76C97508Q33591876-00C6B5FE-6CB5-4855-88E2-22AEEF9DCA00Q36283876-05F1122E-8A8D-4A8A-9DAE-FCD00B0D079AQ38741582-CC76970A-01A3-400C-B947-6003A8564F07Q39022564-11FCC583-332B-4CEA-BC06-B282615B2332Q40208127-67A80883-896E-4595-8CEA-D2DEA144CADBQ42683596-CA32D6EA-32E8-4736-8105-D6535AE8C596Q47109363-0F3EE117-802D-46D2-89CF-E8D966E5125DQ47564468-4339FEEF-0DCB-41CE-8B57-A2BBB0207237Q49851572-B807A007-FB4C-4CE8-A71D-83D03B9146A2Q52577907-E3CA8467-B150-4A0B-800B-601CB83D6E73Q54943060-B0232A9B-171B-4214-ADF0-0A551B903320Q55083652-8439C816-D015-408A-8A82-AB237CB88530Q55296766-257A839E-F6AB-43B3-B432-31813848C5D8Q55347716-6A354FC9-CC3A-4DF5-9FA0-57C38C27E621Q57788678-22046416-3CED-41B5-AAE7-4FF6B4A313EFQ58698521-E086624B-232F-4A5B-BBF4-A96FFD21602E
P2860
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@ast
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@en
type
label
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@ast
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@en
prefLabel
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@ast
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@en
P2093
P2860
P1476
Cytotoxic T lymphocyte antigen ...... r: implications for prognosis.
@en
P2093
Haiming Yu
Jiandong Wang
Junlan Yang
P2860
P2888
P304
P356
10.1007/S00262-015-1696-2
P577
2015-04-17T00:00:00Z